Research News

Jeffrey Teckman, MD

Most Alpha-1 children with liver disease have few symptoms, normal growth

Most children with liver disease due to Alpha-1 Antitrypsin Deficiency have few symptoms and normal growth, according to a new medical journal study.

The report comes from a study of Alpha-1 ZZ and SZ children already known to have  read more…

TAP collaborator Arrowhead begins clinical trials on ARC-AAT to treat Alpha-1 liver disease

A groundbreaking trial of a potential treatment for Alpha-1-related liver disease has begun in Australia.

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, on Monday announced it has started dosing in a Phase 1 clinical trial of ARC-AAT, the  read more…

Robert J. Beall, chief executive of the Cystic Fibrosis Foundation.

Venture capital firm to pay $3.3 billion
to Cystic Fibrosis Foundation, says NYT

A venture capital firm will pay the Cystic Fibrosis Foundation $3.3 billion for future rights to a drug developed for cystic fibrosis that treats 4 percent of people with a form of the disease. The Cystic Fibrosis Foundation will announce  read more…

Vinayak Shenoy, PhD, the study’s lead author.

Plants used to study ways of delivering drugs for pulmonary hypertension

University of Florida researchers are using the leaves of plants to study new ways to deliver drugs that treat pulmonary hypertension, a disease with few treatment options, according to a study published online in the September issue of the journal  read more…

18 grant recipients present research at Foundation’s 2014 Investigators’ Meeting Oct. 17

Foundation Scientific Director Adam Wanner, MD

Eighteen recipients of Alpha-1 Foundation research grants met this week at the third Investigators’ Meeting Scientific Program.

The Foundation sponsors the Investigators’ Meeting every two years to encourage researchers whose work the Foundation has funded  read more…

Foundation-funded study recruiting participants who use supplemental oxygen

Do you use supplemental oxygen? Are you using your oxygen less than the ideal amount of time?

If so, you may be eligible to participate in a research study funded by the Alpha-1 Foundation.

A research team, led by Kristen Holm, PhD,  read more…

Alpha-1 specialist leads new Rare Lung Diseases consortium created through NIH NCATS award

Bruce Trapnell, MD

Pulmonary specialist Bruce Trapnell, MD, director of the Alpha-1 Foundation’s Clinical Resource Center at the Cincinnati Children’s Hospital Medical Center, along with physician researchers at 22 consortia, will collaborate with representatives of 98 patient advocacy groups to  read more…

X-ray of lungs

Clinical trials to begin for stem cell-based lung cancer vaccine

Asterias Biotherapeutics, a subsidiary of BioTime, announced that it partnered with Cancer Research UK (CRUK) and Cancer Research Technology (CRT) to conduct a clinical trial of Asterias’ immunotherapy cancer vaccine, AST-VAC2, for non-small cell lung cancer.

AST-VAC2 is an  read more…

A chest X-ray demonstrating severe COPD.

Two-drug combination best for treating COPD, new study finds

A combination drug therapy aimed at opening the airways and reducing inflammation appears to be the best treatment for older adults with chronic obstructive pulmonary disease (COPD), especially those with asthma, a new study finds.

COPD patients  read more…


Promising results for injectable asthma drug mepolizumab presented at ERS Congress

Investigators for pharmaceutical company GlaxoSmithKline detailed their promising Phase 3 data for the IL-5 biologic mepolizumab in asthma Monday at the European Respiratory Society International Congress in Munich, noting that the injectable halved the rate of exacerbations among a group of patients  read more…


Promising results for asthma drug Reslizumab to be presented at ERS Congress

Teva Pharmaceutical Industries said a drug under development had positive results in reducing the frequency of clinical asthma exacerbations in two advanced trials in patients with moderate to severe asthma.

Reslizumab, an investigational antibody, showed statistically significant reductions in  read more…

Screen Shot 2014-07-15 at 11.36.30 AM

The Alpha-1 Foundation announces
2014-15 grant funding opportunities

Members of the medical, research and scientific communities are invited bring the cure for Alpha-1 Antitrypsin Deficiency within reach by participating in the Alpha-1 Foundation’s research programs.

Get complete information about our research opportunities, application deadlines, application forms and letter of  read more…

A supercooled rat liver sits in the preservation solution in the machine perfusion system. The blue color is caused by antifreeze that surrounds the components of the system to regulate the temperature.

In NIH study, researchers use supercooling technique to preserve liver for transplant

Researchers have developed a new supercooling technique to increase the amount of time human organs could remain viable outside the body. This study was conducted in rats, and if it succeeds in humans, it would enable a world-wide allocation of  read more…


What’s new in Alpha-1 research: vitamin D, a fellowship, a better Research Registry

This week, the Alpha-1 Foundation sent an update on top research news to more than 900 members of the scientific and medical community. Current research-related news the Foundation is highlighting:

Know a brilliant young researcher?
Check out TAP-NCATS fellowship

The Alpha-1 Project (TAP),  read more…


Institute launches lung cancer treatment program; lawmakers urge Medicare pay for CT scan

The National Cancer Institute (NCI) is teaming up with biopharmaceutical companies and patient advocates on a clinical trial program that aims to use genomic profiling to match squamous cell lung cancer patients to treatments based on their individual cancer profiles.

The program, dubbed the Lung Master Protocol  read more…


Two experimental drugs found to slow decline in idiopathic pulmonary fibrosis patients

For the first time, researchers have found drugs that can slow the decline of people with a fatal lung disease, idiopathic pulmonary fibrosis.

Studies of two experimental drugs  read more…

Research poster design

Kamada announces preliminary results of inhaled Alpha-1 therapy clinical trial

Kamada biotherapeutics company on Friday announced preliminary results from its Phase II/III pivotal clinical trial in Europe and Canada of its inhaled augmentation therapy for treating Alpha-1 Antitrypsin Deficiency.

The trial used alpha-1 protein (AAT) inhaled using a nebulizer, and early results  read more…


Five-year study of Alpha-1 liver disease in adults now enrolling

A five-year, multi-center study of Alpha-1 liver disease in adults has enrolled its first participants and is actively recruiting Alphas to take part, says Alpha-1 researcher Jeffrey Teckman, MD, of the Saint Louis University School of Medicine, who is the study’s  read more…

Stem-cell biologist Mahendra Rao has resigned as director of the NIH Center for Regenerative Medicine.

NIH closes stem-cell research program after funding one project, journal reports

Stem-cell researchers at the National Institutes of Health (NIH) are frustrated and confused following the demise of the agency’s Center for Regenerative Medicine (CRM), according to a story published April 8 in Nature science journal.

The program’s director, stem-cell biologist Mahendra  read more…

Gordon L. Snider, MD and widow Sally Everett

Alpha-1 Foundation invites applications for Gordon L. Snider Scholar Award

The Alpha-1 Foundation is accepting applications for a new research grant, the Gordon L. Snider Scholar Award.

The award is named after Gordon L. Snider, MD, one of the most influential researchers in Alpha-1. Snider not only made seminal scientific contributions  read more…